title: Letter from the editor.
authors.affiliation: Senior Vice President R&D and Chief Technology Officer; NasVax, Ltd.; Ness Ziona, Israel.
authors.forename: Ronald
authors.initials: R
authors.lastname: Ellis
authors.forename: Eva M
authors.initials: EM
authors.lastname: Riedmann
mesh_terms: D002644:Chickenpox / Q000453:epidemiology / Q000517:prevention & control; D003226:Congresses as Topic; D006801:Humans; D006973:Hypertension / Q000628:therapy; D007167:Immunotherapy / Q000379:methods*; D007251:Influenza, Human / Q000628:therapy; D008457:Measles / Q000453:epidemiology / Q000517:prevention & control; D008589:Meningococcal Infections / Q000453:epidemiology / Q000517:prevention & control; D009369:Neoplasms / Q000628:therapy; D012400:Rotavirus Infections / Q000453:epidemiology / Q000517:prevention & control; D014612:Vaccines / Q000008:administration & dosage* / Q000276:immunology*
chemical_list: D014612:Vaccines